Primer: Aimed Bio (0009K0 KS) - May 2026
Aimed Bio has demonstrated a remarkable financial turnaround, transitioning from significant losses to profitability, driven by a surge in...
83 Views
Aimed Bio Set for KOSDAQ 150 Fast-Entry: Selvas AI Faces Exit
KRX just announced AimedBio’s Fast-Track inclusion into the KOSDAQ 150, with Selvas AI out. Effective Mar 13, ETF rebalance on Mar 12. Given choppy...
801 Views
A Review of Our IPO Calls in 2025
In this insight, we review our IPO calls in 2025. The accuracy rate of our calls on the IPOs this year was 64%. The overall sentiment on IPOs in...
485 Views
Aimed Bio IPO Book Building Results Analysis
Aimed Bio finalized its IPO price at 11,000 won, which is at the high end of the IPO price range. Aimed Bio will be listed on KOSDAQ on 4 December....
383 Views
Aimedbio IPO Valuation Analysis
Our base case valuation of Aimedbio is implied market cap of 882 billion won or target price of 13,256 won per share over a one year view in 2026.
705 Views